Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    09-November-2000      
Issue 210 Next Update - 14:00 UTC 08:00 EST    10-November-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Additional Drug For Erectile Dysfunction Under Investigation

TAP Pharmaceutical Licenses Investigational ED Compound From Fujisawa

TAP Pharmaceutical Products Inc. today announced that it has in-licensed FR229934, an investigational compound being studied for the treatment of erectile dysfunction (ED) from Fujisawa Pharmaceutical Co., Ltd. Under the license agreement, TAP has exclusive rights to develop this compound and market it on a worldwide basis, except for Japan, South Korea, China and the Republic of China (Taiwan).

FR229934, a phosphodiesterase type 5 (PDE5) inhibitor, was discovered at Fujisawa's research laboratories in Japan and is in preclinical development.

"Along with our currently marketed drug for prostate cancer, Lupron Depot(R), and the development of UPRIMA(R) for erectile dysfunction, the in-licensing of FR229934 significantly enhances and builds upon TAP's strong position in urology," says Thomas Watkins, president of TAP. "Many men with ED are not being adequately treated with currently available therapies. TAP is encouraged by the compound's preliminary data, and we believe it has the potential to help men with ED."

Erectile dysfunction is defined as the inability to attain and maintain an erection sufficient for intercourse. Approximately 30 million Americans suffer from some form of erectile dysfunction.

TAP Pharmaceutical Products Inc. is a joint venture between Abbott Laboratories, headquartered in Abbott Park, Ill., and Takeda Chemical Industries, Ltd. of Osaka, Japan. TAP markets Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of advanced prostate cancer, management of endometriosis, anemia caused by uterine fibroids in combination with iron, and central precocious puberty, and PREVACID(R) (lansoprazole) for the treatment of various acid-related disorders including gastroesophageal reflux disease (GERD) and ulcers. TAP has also submitted a New Drug Application with the FDA for the cephalosporin antibiotic SPECTRACEF(TM) (cefditoren pivoxil), and is currently researching UPRIMA (apomorphine HCl tablets) sublingual for erectile dysfunction.


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.